| Lapatinib |
| N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine |
| (CAS 231277-92-2) |
 |
| Description： |
The epidermal growth factor (EGF) receptors EGFR (ErbB-1) and human EGFR2 (HER2, ErbB-2) are receptor tyrosine kinases that are often over-expressed in cancer.Lapatinib is a potent and selective dual inhibitor of EGFR and HER2 (IC50s = 19 and 3 nM, respectively).It is effective in vivo and is used in combination therapy to prevent or suppress cancers where these kinases are over-expressed, including breast cancer.
|
| Product No. |
KT20008 |
| Product Name |
Lapatinib |
| Synonyms |
Tykerb; GW572016; GW-572016; GW 572016 |
| Formal Name |
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine |
| CAS Number |
231277-92-2 |
| Molecular Formula |
C29H26ClFN4O4S |
| Formula Weight |
581.1 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
1 year |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
AEE788
AG 18
AG-1478
Bosutinib
Erlotinib
BIBW 2992
Mubritinib
Pelitinb
|
|
